StemEdit
Advanced Stem Cell Gene Editing Service

StemEdit is REPROCELL’s advanced genome-editing service, tailored specifically for iPSCs. Whether your goal is to support cutting-edge research or generate gene-edited iPSC lines for clinical applications, our expert team provides high-precision gene modifications designed to meet your exact project requirements.

REPROCELL enables you to obtain the precise genotype required, saving time and resources ahead of large-scale cell bank production. You may provide your own iPSCs or select from our research- and clinical-grade iPSC clones.

Alternatively, we can generate custom iPSC lines, tailored to your specific project goals. Contact us for more details.

High-Precision Genome Editing for Stem Cells

The StemEdit service delivers high-precision gene editing in stem cells, enabling complex modifications early in your project development. Optimized for a variety of nuclease systems (including caspases (Cas enzymes)), StemEdit achieves challenging edits reliably, helping to reduce risk and accelerate progression to downstream cell bank manufacturing.

Examples of genetic modifications include:

• Knock-in of large gene fragments
• Knock-in of biallelic mutations
• Knock-out of multiple genes 
• Incorporation of reporter or selection genes

Global StemEdit Facilities: Gene Editing in USA & Japan

StemEdit projects can be carried out at either our REPROCELL USA facility in Beltsville, Maryland, or at our REPROCELL Japan GMP Manufacturing Facility, depending on your project’s scope and logistical needs. Choose the location that best matches your timelines, regulatory requirements, and desired throughput. 

Creating The Basis for Hypoimmune Clinical iPSCs by B2M/CIITA Double Knock-out

HLA expression was confirmed at the protein level by flow cytometry in iPSC lines with with B2M and CIITA double knockouts. Because Class II HLA expression is regulated post-differentiation, Class II levels were assessed in macrophages differentiated from iPSCs (right: anti-HLA-DR antibody). Both Class I and II HLA expression is suppressed in the B2M/CIITA knockout line, demonstrating that REPROCELLs StemEdit genome editing technology can generate iPSCs designed to minimize immune rejection.

Contact us if you have any requests using the inquiry form below.

StemEdit B2M/CIITA knockout iPSCs provide a powerful, immune-evasive foundation for the development of next-generation cell therapy products.

HLA Class I and II expression in B2M/CIITA double knock-out iPSCs. HLA expression was measured by flow cytometry in unedited parental iPSC line and after knock-out of B2M and CIITA genes. Expression of HLA I and II is suppressed in B2M/CIITA knockout lines. Results indicate that the generation of iPSC for the purpose of suppressing an immune rejection is successful with StemEdit.

(A.) HLA Class I expression was measured in the parental iPSC-derived macrophages by flow cytometry.

(B.) Undifferentiated iPSCs (“Parental iPSCs”) do not express HLA II. Expression of HLA Class II occurs only in cells post differentiation. Expression of HLA II gene HLA-DR was therefore measured in iPSC-derived macrophages.